GOSS, US38341P2011

Gossamer Bio stock gained 1.22 percent on October 6 after FDA filing supporter ????? no

Published on 10/07/2026 at 04:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gossamer Bio stock was last at USD 10.78 on October 6, 2026, after a 1.22 percent daily gain. Q2 revenue fell to USD 9.238 million, while seven analysts set a USD 90 median target.

GOSS, US38341P2011, Illustration mit AI erstellt.

Gossamer Bio (ISIN US38341P2011) was last at USD 10.78 on Nasdaq on October 6, 2026, up 1.22 percent from the prior session. The company submitted its first New Drug Application for seralutinib to the FDA on September 23, 2026, a regulatory milestone for its pulmonary arterial hypertension program, according to the SEC filing.

Seralutinib reaches FDA review

The NDA is supported by the Phase 3 PROSERA study, the Phase 2 TORREY study and additional analyses. The FDA will decide whether to accept the application for filing after its initial review, while the company said the filing could be accepted later in 2026, according to the SEC filing.

The regulatory case still carries a measurable clinical hurdle. PROSERA produced a 13.3-meter placebo-adjusted improvement in six-minute walk distance with a p-value of 0.0320, while the study had used a 0.025 significance threshold, according to Quartr.

Revenue falls in Q2 2026

Gossamer reported USD 9.238 million of revenue in the quarter ended June 30, 2026, down from USD 16.955 million in the previous quarter. Diluted EPS was negative USD 0.08, while net income was USD 16.900 million, according to Investing.com.

The balance between regulatory progress and operating figures is central to the stock. Gossamer had USD 41.148 million in cash and cash equivalents at June 30, 2026, while operating cash flow for the quarter was negative USD 39.424 million.

Analysts keep a wide target range

Seven analysts tracked by Ticker Nerd show three Buy, three Hold and one Sell rating, with a median 12-month price target of USD 90. Targets span USD 22 to USD 120, placing the median target USD 79.22 above the October 6 price.

H.C. Wainwright kept a Buy rating and lifted its split-adjusted target from USD 2 to USD 90 on September 21, 2026, according to Markets Insider. The revision followed Gossamer's 1-for-80 reverse stock split and shows why target comparisons require the post-split share structure.

Gossamer Bio stock stays volatile

Gossamer Bio stock was last at USD 10.78 on Nasdaq at 4:00 p.m. ET on October 6, 2026, with a market capitalization of USD 65.9 million and volume of 197,167 shares. Its 52-week range was USD 9.10 to USD 309.60, leaving the regulatory decision on seralutinib as the clearest company-specific valuation checkpoint.